Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).
1 finding from 1 review
Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical remission as defined by the studies at weeks 24–26 compared with purine analogues alone (moderate certainty).
1 finding from 1 review
Clinical response as defined by the studies at week 26 · Patients with active Crohn's disease
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
Infliximab combined with purine analogues probably leads to lower clinical relapse (at 48 weeks, CDAI of 150 or greater together with… compared with purine analogues (moderate certainty).
1 finding from 1 review
Loss of clinical response · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events (at 48 weeks to 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Intervention not reported
Infliximab (2 RCTs; 21 participants) · surgically induced remission in Crohn's disease
The intervention showed no clear difference in infliximab (2 RCTs; 21 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Infliximab (1 RCT; 11 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes infliximab (1 RCT; 11 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Infliximab (2 RCTs; 21 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes infliximab (2 RCTs; 21 participants) (very low certainty).
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Azathioprine probably leads to lower clinical remission compared with infliximab (moderate certainty).
1 finding from 1 review
Clinical remission off steroids · Patients with active Crohn's disease
Azathioprine probably leads to lower clinical remission off steroids compared with infliximab (moderate certainty).
1 finding from 1 review
Mucosal healing · Patients with active Crohn's disease
Azathioprine probably leads to lower mucosal healing compared with infliximab (moderate certainty).
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review